RTKs can be targeted in cancer therapy using small molecule inhibitors and monoclonal antibodies. Small molecule inhibitors, such as tyrosine kinase inhibitors (TKIs), block the kinase activity of RTKs, preventing downstream signaling. Monoclonal antibodies, on the other hand, bind to the extracellular domain of RTKs, preventing ligand binding and receptor activation.